14 January 2019 - - US-based biomaterials and biotechnology company InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) has appointed Richard Christopher as its chief financial officer and treasurer, effective January 14, 2019, the company said.

Prior to joining InVivo, Christopher was the chief financial officer of iCAD, Inc., a NASDAQ-listed company with a focus on therapies and solutions for the early identification and treatment of cancer.

Before iCAD, Inc., Christopher was chief financial officer and chief operating officer of Caliber Imaging and Diagnostics, Inc., a medical technology company focused on cancer detection imaging solutions, with primary applications in dermatology.

Prior to Caliber, Christopher held various positions of increasing responsibility at DUSA Pharmaceuticals, Inc., a company focused on the treatment of precancerous skin lesions, where he ultimately served as chief financial officer through its acquisition and integration into Sun Pharmaceuticals Industries Ltd.

Christopher holds a Master of Science in Accounting from Suffolk University and a Bachelor of Science in Finance from Bentley University.

InVivo Therapeutics Holdings is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries.

The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children's Hospital and who now is affiliated with Massachusetts General Hospital.

In January 2018, the company announced updated clinical evidence, including improvements in patients with acute spinal cord injury, from its INSPIRE study of the Neuro-Spinal Scaffold.

The publicly traded company is headquartered in Cambridge, MA.